These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The prostate specific antigen. Its use as a tumor marker for prostate cancer. Kantoff PW; Talcott JA Hematol Oncol Clin North Am; 1994 Jun; 8(3):555-72. PubMed ID: 8707772 [TBL] [Abstract][Full Text] [Related]
3. A guideline to clinical utility of prostate specific antigen. Farhat WA; Habbal AA; Khauli RB Saudi Med J; 2000 Mar; 21(3):223-7. PubMed ID: 11533789 [TBL] [Abstract][Full Text] [Related]
4. Rising prostate specific antigen after radical prostatectomy: a case based review. Nasr R; Goldenberg SL Can J Urol; 2001 Aug; 8(4):1306-13. PubMed ID: 11564273 [TBL] [Abstract][Full Text] [Related]
5. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes. Barry MJ; Fleming C; Coley CM; Wasson JH; Fahs MC; Oesterling JE Urology; 1995 Sep; 46(3):277-89. PubMed ID: 7544931 [No Abstract] [Full Text] [Related]
6. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience]. Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203 [TBL] [Abstract][Full Text] [Related]
8. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?--A case control study. Khatami A; Damber JE; Lodding P; Pihl CG; Hugosson J Scand J Urol Nephrol; 2003; 37(3):213-7. PubMed ID: 12775279 [TBL] [Abstract][Full Text] [Related]
9. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer]. Zhao XJ; Kong XB; Wang WH Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882 [TBL] [Abstract][Full Text] [Related]
10. Contemporary view of prostate cancer diagnosis and treatment. Costello AJ Aust Fam Physician; 2003 Jun; 32(6):396-8. PubMed ID: 12833761 [No Abstract] [Full Text] [Related]
11. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens. Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932 [TBL] [Abstract][Full Text] [Related]
13. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983 [TBL] [Abstract][Full Text] [Related]
14. Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both? Carroll PR J Urol; 2005 Apr; 173(4):1061-2. PubMed ID: 15758699 [No Abstract] [Full Text] [Related]
16. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Khatami A; Hugosson J; Wang W; Damber JE Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies. Stewart J; Fleshner N; Cole H; Toi A; Sweet J J Urol; 2008 May; 179(5):1751-5; discussion 1755. PubMed ID: 18343427 [TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776 [TBL] [Abstract][Full Text] [Related]
19. Early versus delayed intervention for prostate cancer: the case for early intervention. Loeb S; Catalona WJ Nat Clin Pract Urol; 2007 Jul; 4(7):348-9. PubMed ID: 17563779 [No Abstract] [Full Text] [Related]
20. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. Zietman AL; Thakral H; Wilson L; Schellhammer P J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]